Table 3.
Correlative studies for 25 available pathologic samples from patients on S0312, by categories of RECIST response
| RECIST best response | ||
|---|---|---|
| Tumor Marker | Progressive Disease (n(%)) | Stable or better (n(%)) |
| PTEN (% cells expressing)* | ||
| 0 | 3/6 (50) | 13/14 (93) |
| >0 | 3/6 (50) | 1/14 (7) |
| pAKT (% cells expressing)* | ||
| 0 | 5/6 (83) | 13/14 (93) |
| >0 | 1/6 (17) | 1/14 (7) |
| pmTOR (% cells expressing)* | ||
| 0 | 4/6 (67) | 4/14 (29) |
| >0 | 2/6 (33) | 10/14 (71) |
| vHL** | ||
| mutation in Exon 1 | 2/4 (50) | 3/9 (33) |
| mutation in Exon 2 | 0/4 (0) | 2/9 (22) |
| mutation in Exon 3 | 1/4 (25) | 0/9 (0) |
| TS Polymorphism*** | ||
| -6/-6 | 1/6 (17) | 3/15 (20) |
| +6/-6 | 3/6 (50) | 8/15 (53) |
| +6/+6 | 2/6 (33) | 4/15 (27) |
| ERCC1 Mean Normalized Expression | ||
| Minimum | 0.00130 | 0.00043 |
| Q1 | 0.00143 | 0.00087 |
| Median | 0.00199 | 0.00288 |
| Q3 | 0.00348 | 0.00385 |
| Maximum | 0.00352 | 0.00858 |
*
sample viable for testing in 20 of 26 patients
**
sample viable for testing in 13 of 26 patients (see text)
***
sample viable for testing in 21 of 26 patients
****sample viable for testing in 23 of 26 patients. Mean Normalized Expression (MNE) calculated using method outlined by Simon 25. MNE is a ratio comparing ERCC1 to a reference gene (beta-actin).